You are here
Practical management of advanced mCRPC: Summary of key data and guideline recommendations
Management of advanced metastatic castration resistant prostate cancer (mCRPC) has dramatically changed. Professor Axel Merseburger, University Hospital Schleswig-Holstein, Lübeck, highlights the most important studies on which the second-line treatment options of the EAU guidelines 2016 are based on. He presents the data for overall survival and adverse effects for docetaxel, cabazitaxel (TROPIC study), abiraterone/prednisone (COU-AA-301), enzalutamide (AFFIRM) and radium-223 (ALSYMPCA). Data for combination options, sequencing strategies and prevalence of AR-V7 to predict treatment response are presented.